Latest Videos Archives

Diet and Prostate Cancer: What We Need to Know to Tell our Patients

Posted by Stacy Loeb, MD | Feb 2025

Stacy Loeb, MD, MSc, PhD (hon), emphasizes integrating dietary and lifestyle modifications into prostate cancer management to improve patient outcomes. In this 21-minute presentation, Dr. Loeb notes that patients with localized disease are more likely to die from cardiovascular causes than prostate cancer itself, highlighting the opportunity to address broader health concerns.

Dr. Loeb introduces the six pillars of lifestyle medicine: whole food, plant-predominant nutrition, physical activity, restorative sleep, avoidance of toxic substances, social connection, and stress management. She emphasizes that plant-based diets, particularly whole foods, and plant-based patterns, reduce the risk of prostate cancer, cardiovascular disease, and erectile dysfunction while promoting environmental sustainability.

Loeb advocates for accessible patient resources, tailored educational materials, and collaboration among healthcare providers to promote these practices. The discussion addresses the importance of patient-centered approaches and the potential role of testosterone management in prostate cancer care.

Post-Treatment Assessment and Creating Imaging-Based Short- and Intermediate-Term Patient Outcomes

Posted by Faina Shtern, MD | Feb 2025

Faina Shtern, MD, introduces an international group to advance research and clinical strategies for focal treatment of prostate cancer.

Role of Digital Pathology and AI in Improving Diagnostic Accuracy

Posted by David G. Bostwick, MD, MBA, FCAP | Feb 2025

David G. Bostwick, MD, MBA, FCAP, explores the role of artificial intelligence (AI) and digital pathology in advancing diagnostic accuracy in prostate cancer. In this 19-minute presentation, Dr. Bostwick addresses the limitations of using biopsies and radical prostatectomies as the gold standard in prostate cancer diagnosis. Despite its high initial costs and operational challenges, he emphasizes that digital pathology holds transformative potential for standardization and efficiency in pathology practices.

Dr. Bostwick delves into the long-standing application of AI in pathology, highlighting its ability to reduce human workloads. Advances in digital pathology have improved resolution, speed, and data transfer capabilities, enabling better integration of AI tools for detecting and grading cancer.

Dr. Bostwick asserts the future of pathology lies in 3D optical slicing and deep learning algorithms, which allow for precise tumor quantification and three-dimensional reconstructions of tissues. These methods could revolutionize grading systems, offering unparalleled accuracy and data granularity.

Point Counterpoint: Risk Stratification for Biopsy – Biomarkers

Posted by Juan Javier-DesLoges, MD, MS | Feb 2025

Juan Javier-DesLoges, MD, MS, focuses on contemporary advancements in prostate cancer detection, emphasizing the integration of biomarkers and MRI for biopsy decision-making. In this 5-minute presentation, he references recent guidelines, which advocate biomarkers and MRI as tools for determining the necessity of biopsies. Studies comparing biomarkers such as 4K, PHI, SelectMDx, and XODX illustrate their ability to enhance the specificity and accuracy of cancer detection compared to PSA alone.

Dr. Javier-DesLoges stresses that MRI further refines risk stratification when combined with biomarkers. He underscores the complementary role of these tools, advocating their combined use to optimize diagnostic outcomes for patients with intermediate PSA levels.

Point Counterpoint: Risk Stratification for Biopsy – MRI

Posted by Peter A. Pinto, MD | Feb 2025

Peter A. Pinto, MD, underscores the evolving role of MRI as a critical biomarker in urologic oncology, particularly for prostate cancer detection, staging, and treatment planning.

In this 12-minute conversation, Dr. Pinto highlights MRI’s unique position as a diagnostic and procedural adjunct, emphasizing its ability to improve biopsy accuracy, reduce over-diagnosis of low-grade cancers, and enhance focal therapy targeting. He shares that MRI provides actionable insights that enhance clinical decision-making by correlating radiologic findings with pathological outcomes. Further, the potential of MRI as a screening tool is explored, with promising advancements in shorter, contrast-free scans. Dr. Pinto also addresses the integration of AI for tumor identification, segmentation, and quality control, presented as a pathway to overcoming these limitations.